Lactococcus lactis as a cell factory for delivery of therapeutic proteins

Research output: Contribution to journalReview articlepeer-review

Abstract

The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which re- combinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.

Original languageEnglish
Pages (from-to)34-45
Number of pages12
JournalCurrent Gene Therapy
Volume10
Issue number1
DOIs
Publication statusPublished - Feb 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Delivery
  • IBD
  • Immunomodulation
  • Lactococcus
  • Therapeutic protein
  • Vaccine
  • Vector

Fingerprint

Dive into the research topics of 'Lactococcus lactis as a cell factory for delivery of therapeutic proteins'. Together they form a unique fingerprint.

Cite this